sarcomatoid RCC

• 

ESMO 2019: First-line avelumab plus axitinib in sarcomatoid kidney cancer – results from JAVELIN Renal 101

By Sharon Kell|2019-10-03T07:45:31+00:003 Oct 2019|Drug treatments|

Results from the JAVELIN Renal 101 study to evaluate avelumab [...]

Read More

Comments Off on ESMO 2019: First-line avelumab plus axitinib in sarcomatoid kidney cancer – results from JAVELIN Renal 101

• 

ESMO 2019: Results from JAVELIN-Renal 101 trial for sarcomatoid kidney cancer

By Sharon Kell|2019-09-30T10:40:26+00:0030 Sep 2019|Drug treatments|

Results from the JAVELIN-Renal 101 clinical trial to assess avelumab [...]

Read More

Comments Off on ESMO 2019: Results from JAVELIN-Renal 101 trial for sarcomatoid kidney cancer

• 

‘Revolutionary’ tumour agnostic drug approved for use in Europe

By Sharon Kell|2019-09-25T09:38:33+00:0025 Sep 2019|Drug treatments|

Described by NHS England as "revolutionary" and an "exciting new [...]

Read More

Comments Off on ‘Revolutionary’ tumour agnostic drug approved for use in Europe

• 

ASCO 2019: Treatment of sarcomatoid kidney cancer

By Sharon Kell|2019-06-06T14:44:16+00:006 Jun 2019|Drug treatments|

The following presentation from the American Society of Clinical Oncology [...]

Read More

Comments Off on ASCO 2019: Treatment of sarcomatoid kidney cancer

• 

Clinical course and treatment outcomes of sarcomatoid chromophobe RCC

By Sharon Kell|2019-05-21T07:59:08+00:0021 May 2019|Cancer news|

Chromophobe renal cell carcinoma (RCC) is a rare subtype of [...]

Read More

Comments Off on Clinical course and treatment outcomes of sarcomatoid chromophobe RCC

• 

ASCO GU 2019: Atezolizumab and bevacizumab in non-clear cell kidney cancer and sarcomatoid kidney cancer

By Sharon Kell|2019-02-26T12:51:10+00:0026 Feb 2019|Subtypes of RCC|

Results from this trial for patients with non-clear cell renal [...]

Read More

Comments Off on ASCO GU 2019: Atezolizumab and bevacizumab in non-clear cell kidney cancer and sarcomatoid kidney cancer

• 

ASCO GU 2019: Gemcitabine plus axitinib in patients with sarcomatoid renal cell carcinoma (RCC)

By Sharon Kell|2019-02-26T10:07:18+00:0026 Feb 2019|Subtypes of RCC|

Results from this trial for sarcomatoid renal cell carcinoma (RCC) [...]

Read More

Comments Off on ASCO GU 2019: Gemcitabine plus axitinib in patients with sarcomatoid renal cell carcinoma (RCC)

• 

An overview of the management of rare subtypes of kidney cancer

By Sharon Kell|2018-06-07T08:36:49+00:007 Jun 2018|Drug treatments|

This interview with Dr Ramaprasad Srinivasan from the National Cancer Institute in [...]

Read More

Comments Off on An overview of the management of rare subtypes of kidney cancer